Home > Urology > EAU 2020 > Prostate Cancer & Imaging > PSMA PET-CT staging is 27% more accurate

PSMA PET-CT staging is 27% more accurate

Principal Investigator
Prof. Michael Hofman, Peter MacCallum Cancer Centre, Australia

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
EAU 2020
Trial
ProPSMA
Labelled prostate-specific membrane antigen (PSMA) in PET-CT fusion (PSMA PET-CT) was superior in specificity and sensitivity to conventional imaging in pre-treatment staging of intermediate- and high-risk localised prostate cancer. Prof. Michael Hofman (Peter MacCallum Cancer Centre, Australia) presented the results of the ProPSMA study, which was recently also published in The Lancet [1,2]. The rationale of the study was that pre-treatment staging of intermediate- and high-risk localised prostate cancer is important for treatment choice, yet current standard imaging has limited sensitivity. The study investigated whether imaging using PSMA PET-CT was superior to conventional imaging in pre-treatment staging. Men with histologically confirmed prostate cancer who were being considered for curative-intent radic...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on